ArticleJournal of clinical medicine2022

Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations.

Gemma Burdge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.